Dr. Sanati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd
# SB290
West Hollywood, CA 90048Phone+1 310-248-6240Fax+1 310-439-1906
Education & Training
- Yale-New Haven Medical CenterFellowship, Gynecologic Pathology, 2008 - 2009
- Washington University/B-JH/SLCH ConsortiumFellowship, Cytopathology, 2006 - 2007
- Washington University/B-JH/SLCH ConsortiumFellowship, Selective Pathology, 2005 - 2006
- University of Texas Medical Branch HospitalsResidency, Pathology-Anatomic and Clinical, 2001 - 2005
- Iran University of Medical SciencesClass of 1993
Certifications & Licensure
- CA State Medical License 2015 - 2025
- IL State Medical License 2016 - 2020
- MO State Medical License 2007 - 2020
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Cytopathology
Clinical Trials
- PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Start of enrollment: 2013 Apr 10
- Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer Start of enrollment: 2014 Aug 01
- Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer Start of enrollment: 2014 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- 216 citationsKi67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American Co...Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Franco Gonçalves, Souzan Sanati
Journal of Clinical Oncology. 2017-04-01 - 225 citationsNeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew P. Goetz
Clinical Cancer Research. 2017-08-01 - 107 citationsProteogenomic integration reveals therapeutic targets in breast cancer xenograftsKuan-lin Huang, Shunqiang Li, Philipp Mertins, Song Cao, Harsha P. Gunawardena
Nature Communications. 2017-03-28
Journal Articles
- Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer XenograftsSouzan Sanati, Jana W Qiao, Xian Chen, Matthew J Ellis, Cynthia Ma, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: